The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citationMelnick, V. L., & Dubler, N. N. (1985) · Contemporary Issues in Biomedicine, Ethics, and Society · doi:10.1007/978-1-4612-5174-3 · Cited by 1,986
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citationBrookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,802
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Self-citationDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Self-citationDickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Self-citationFrequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Sperling, R. A., LaViolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., Marshall, G., Hyman, B. T., Selkoe, D. J., Hedden, T., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.003 · Cited by 1,027
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Self-citationFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Self-citationJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Self-citationLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
Self-citationDementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Self-citationReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
Self-citationEpisodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684
Arriagada, P. V., Marzloff, K., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.9.1681 · Cited by 638
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Self-citationSheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., & Mintun, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.024 · Cited by 597
2009 Alzheimer's disease facts and figures
Alzheimer's Association (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.03.001 · Cited by 555
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Self-citationMorris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Self-citationAge-Specific Incidence of Alzheimer's Disease in a Community Population
Hebert, L. E. (1995) · JAMA · doi:10.1001/jama.1995.03520410048025 · Cited by 462
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462
Sheline, Y. I., Morris, J. C., Snyder, A. Z., Price, J. L., Yan, Z., D’Angelo, G., Liu, C., Dixit, S., Benzinger, T. L. S., Fagan, A. M., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-10.2010 · Cited by 444
Self-citationImaging amyloid deposition in Lewy body diseases
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443
Cognition, reserve, and amyloid deposition in normal aging
Rentz, D. M., Locascio, J. J., Becker, J. A., Moran, E. K., Eng, E., Buckner, R. L., Sperling, R. A., & Johnson, K. A. (2009) · Annals of Neurology · doi:10.1002/ana.21904 · Cited by 420
Self-citationReimagining Alzheimer's Disease—An Age-Based Hypothesis
Herrup, K. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4521-10.2010 · Cited by 408
MRI and CSF biomarkers in normal, MCI, and AD subjects
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 406
Self-citationRelation of cognitive activity to risk of developing Alzheimer disease
Wilson, R. S., Scherr, P. A., Schneider, J. A., Tang, Y., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271087.67782.cb · Cited by 400
Self-citationPredictors of maintaining cognitive function in older adults: The Health ABC Study
Yaffe, K., Fiocco, A. J., Lindquist, K., Vittinghoff, E., Simonsick, E. M., Newman, A. B., Satterfield, S., Rosano, C., Rubin, S. M., Ayonayon, H. N., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a92c36 · Cited by 396
Self-citationKlunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Depressive Symptoms and Cognitive Decline in Late Life: A Prospective Epidemiological Study
Ganguli, M., Du, Y., Dodge, H. H., Ratcliff, G. G., & Chang, C.-C. H. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.153 · Cited by 314
Storandt, M., Mintun, M. A., Head, D. M., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 309
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P. T., Savage, G. R., Ng, S., Ackermann, U., Cowie, T., Currie, J. N., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 302
Self-citationLongitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ 11 C]PiB
Resnick, S. M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D. P., Dannals, R. F., Mathis, C. A., Klunk, W. E., Ferrucci, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d3e3e9 · Cited by 288
Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
Pimplikar, S. W., Nixon, R. A., Robakis, N. K. R. K., Shen, J., & Tsai, L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4305-10.2010 · Cited by 287
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 275
Self-citationChronic Psychological Distress and Risk of Alzheimer’s Disease in Old Age
Wilson, R. S., Arnold, S. E., Schneider, J. A., Kelly, J. F., Tang, Y., & Bennett, D. A. (2006) · Neuroepidemiology · doi:10.1159/000095761 · Cited by 266
Self-citationAssociation of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline
Yaffe, K. S. (2011) · JAMA · doi:10.1001/jama.2010.1995 · Cited by 245
Self-citationFotenos, A. F., Mintun, M. A., Snyder, A. Z., Morris, J. C., & Buckner, R. L. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.27 · Cited by 226
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198
Early-Stage and Preclinical Alzheimer Disease
&NA; (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000184005.22611.cc · Cited by 197
Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project
Ganguli, M., Dodge, H. H., Chen, P., Belle, S., & DeKosky, S. T. (2000) · Neurology · doi:10.1212/wnl.54.5.1109 · Cited by 196
Lee, H., Casadesús, G., Zhu, X., Takeda, A., Perry, G. L., & Smith, M. A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1297.001 · Cited by 183
Epidemiology of Apathy in Older Adults: The Cache County Study
Onyike, C. U., Leoutsakos, J., Tschanz, J. T., Norton, M. C., Green, R. C., Steinberg, M., Welsh-Bohmer, K. A., Breitner, J. C. S., & Lyketsos, C. G. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000235689.42910.0d · Cited by 182
Trajectory of mild cognitive impairment onset
Howieson, D. B., Carlson, N. E., Moore, M. M., Wasserman, D. K., ABENDROTH, C. D., Payne-Murphy, J. C., & Kaye, J. A. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080375 · Cited by 167
Self-citationChételat, G., Villemagne, V. L., Pike, K. E., Ellis, K. A., Bourgeat, P., Jones, G. R., O'Keefe, G. J., Salvado, O., Szoeke, C. E. I., Martins, R. N., et al. (2011) · Brain · doi:10.1093/brain/awq383 · Cited by 159
Self-citationSerial MRI and CSF biomarkers in normal aging, MCI, and AD
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7ca82 · Cited by 154
Self-citationIncreased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
Schott, J. M., Bartlett, J. W., Fox, N. C., Barnes, J., & Initiative, A. D. N. (2010) · Annals of Neurology · doi:10.1002/ana.22315 · Cited by 146
Cognitive activity and the cognitive morbidity of Alzheimer disease
Wilson, R. S., Barnes, L. L., Aggarwal, N. T., Boyle, P. A., Hebert, L. E., de Leon, C. F. M., & Evans, D. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f25b5e · Cited by 125
Brain Atrophy in Healthy Aging Is Related to CSF Levels of Aβ1-42
Fjell, A. M., Walhovd, K. B., Fennema‐Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., Blennow, K., Brewer, J. B., Dale, A. M., & Initiative, T. A. D. N. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp279 · Cited by 106
β-Amyloid affects frontal and posterior brain networks in normal aging
Oh, H., Mormino, E. C., Madison, C. M., Hayenga, A. O., Smiljic, A., & Jagust, W. J. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.027 · Cited by 104
Familial Alzheimer disease: Decreases in CSF Aβ 42 levels precede cognitive decline
Moonis, M., Swearer, J. M., Dayaw, M. P. E., George‐Hyslop, P. S., Rogaeva, E. A., Kawarai, T., & Pollen, D. A. (2005) · Neurology · doi:10.1212/01.wnl.0000171397.32851.bc · Cited by 95
Selective Disruption of the Cerebral Neocortex in Alzheimer's Disease
Desikan, R. S., Sabuncu, M. R., Schmansky, N. J., Reuter, M., Cabral, H., Hess, C. P., Weiner, M. W., Biffi, A., Anderson, C. D., Rosand, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012853 · Cited by 83
Self-citationMontine, T. J., Peskind, E. R., Quinn, J. F., Wilson, A. M., Montine, K. S., & Galasko, D. R. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8126-6 · Cited by 77
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“In the case of preclinical AD, biomarkers were used to define the construct [4].”
InfluentialSelf-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citation
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
